文献速递炎症性肠病

系统综述与网络Meta分析:不同静脉铁剂治疗炎症性肠病患者缺铁性贫血的比较疗效与耐受性

Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2017-03-21

该网络Meta分析纳入5项随机对照试验(n=1143)比较静脉铁剂治疗炎症性肠病缺铁性贫血的疗效,仅羧基麦芽糖铁显著优于口服铁(OR=1.9,95%CrI 1.1-3.2);系统综述汇总1746例患者显示各铁剂不良事件率不同,羧基麦芽糖铁最有效且耐受性趋好。

要点

  • 仅羧基麦芽糖铁较口服铁显著提高治疗反应(OR=1.9,95%CrI 1.1-3.2)。
  • 排序概率显示羧基麦芽糖铁最有效,其次为蔗糖铁、异麦芽糖酐铁和口服铁。
  • 羧基麦芽糖铁、蔗糖铁、右旋糖酐铁、异麦芽糖酐铁不良事件率分别为12.0%、15.3%、12.0%、17.0%。

核心结论

  • 羧基麦芽糖铁是最有效的静脉铁剂,其次为蔗糖铁,且羧基麦芽糖铁耐受性趋好。
  • 纳米胶体静脉铁产品疗效与安全性特征不同,不可互换。

研究设计与样本

  • 系统综述与贝叶斯网络Meta分析,PROSPERO注册号42016046565。
  • 2016年6月系统检索分析静脉铁剂治疗炎症性肠病缺铁性贫血疗效与安全性的研究。
  • 网络Meta分析纳入5项随机对照试验共1143例患者;系统综述汇总1746例患者。

主要发现

  • 仅羧基麦芽糖铁显著优于口服铁(OR=1.9,95%CrI 1.1-3.2)。
  • 排序概率显示羧基麦芽糖铁最有效,依次为蔗糖铁、异麦芽糖酐铁和口服铁。
  • 系统综述汇总不良事件率:羧基麦芽糖铁12.0%、蔗糖铁15.3%、右旋糖酐铁12.0%、异麦芽糖酐铁17.0%。
  • 羧基麦芽糖铁和异麦芽糖酐铁各报告1例药物相关严重不良事件,蔗糖铁报告1例可能药物相关严重不良事件。

关键数值与推荐

  • 主要结局为治疗反应,定义为血红蛋白正常化或升高≥2 g/dL。
  • 现行欧洲指南推荐对严重贫血或口服铁剂不耐受的炎症性肠病患者使用静脉铁剂治疗。

临床怎么用

  • 现行欧洲指南推荐对严重贫血或口服铁剂不耐受的炎症性肠病患者使用静脉铁剂治疗。
  • 作者认为羧基麦芽糖铁是最有效的静脉铁剂,其次为蔗糖铁,且耐受性趋好。
  • 作者认为纳米胶体静脉铁产品不可互换。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Iron deficiency anaemia (IDA) is a common complication of inflammatory bowel disease (IBD) associated with reduced quality of life and increased hospitalisation rates. While the best way of treating IDA in IBD patients is not clearly established, current European guidelines recommend intravenous iron therapy in IBD patients with severe anaemia or intolerance to oral iron compounds. AIM: To compare the efficacy and tolerability of different intravenous iron formulations used to treat IDA in IBD patients in a systematic review and Bayesian network meta-analysis (NMA), PROSPERO registration number: 42016046565. METHODS: In June 2016, we systematically searched for studies analysing efficacy and safety of intravenous iron for IDA therapy in IBD. Primary outcome was therapy response, defined as Hb normalisation or increase ≥2 g/dL. RESULTS: Five randomised, controlled trials (n = 1143 patients) were included in a network meta-analysis. Only ferric carboxymaltose was significantly more effective than oral iron [OR=1.9, 95% CrI: (1.1;3.2)]. Rank probabilities showed ferric carboxymaltose to be most effective, followed by iron sucrose, iron isomaltose and oral iron. Pooled data from the systematic review (n = 1746 patients) revealed adverse event rates of 12.0%, 15.3%, 12.0%, 17.0% for ferric carboxymaltose, iron sucrose, iron dextran and iron isomaltose respectively. One drug-related serious adverse event (SAE) each was reported for ferric carboxymaltose and iron isomaltoside, and one possibly drug-related SAE for iron sucrose. CONCLUSIONS: Ferric carboxymaltose was the most effective intravenous iron formulation, followed by iron sucrose. In addition, ferric carboxymaltose tended to be better tolerated. Thus, nanocolloidal IV iron products exhibit differing therapeutic and safety characteristics and are not interchangeable.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Aksan A, Işık H, Radeke HH, et al. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017. PMID: 28326596. doi:10.1111/apt.14043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。